Zoetis Inc. $ZTS Shares Sold by Caldwell Trust Co

Caldwell Trust Co trimmed its position in Zoetis Inc. (NYSE:ZTS) by 64.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,267 shares of the company’s stock after selling 7,732 shares during the period. Caldwell Trust Co’s holdings in Zoetis were worth $537,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Global Wealth Strategies & Associates acquired a new stake in Zoetis in the fourth quarter worth approximately $25,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Zoetis during the 3rd quarter valued at $31,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis during the 4th quarter valued at $30,000. Holos Integrated Wealth LLC acquired a new stake in shares of Zoetis during the 4th quarter valued at $32,000. Finally, Financial Consulate Inc. acquired a new stake in shares of Zoetis during the 3rd quarter valued at $39,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ZTS. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. UBS Group cut their price objective on Zoetis from $136.00 to $130.00 and set a “neutral” rating for the company in a research report on Tuesday. Citigroup began coverage on Zoetis in a research report on Wednesday, April 15th. They set a “buy” rating and a $145.00 price objective for the company. Piper Sandler reiterated a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Finally, Bank of America increased their price objective on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $151.75.

Zoetis Price Performance

ZTS opened at $116.74 on Wednesday. The stock has a fifty day moving average of $120.48 and a 200-day moving average of $124.93. The firm has a market capitalization of $49.11 billion, a P/E ratio of 19.39, a PEG ratio of 1.80 and a beta of 0.98. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts forecast that Zoetis Inc. will post 7.02 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.